Recent Development in Germany Bladder Cancer Diagnosis and Treatment Landscape

Germany bladder cancer market is estimated to grow considerably, at a CAGR of around 9.9% during the forecast period (2024-2031). The market growth is driven by the increasing geriatric population, the presence of highly specialized urologists for cancer treatment, and a bit lower cost treatment as compared to the UK, attracting medical tourism in the country. Additionally, Germany has a well-developed healthcare system and favorable government policies, which are contributing to the market in the region.

Browse the full report description of “Germany Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2024-2031” at https://www.omrglobal.com/industry-reports/germany-bladder-cancer-market

Germany bladder cancer market is segmented into cancer type, diagnosis, treatment, and geography. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, Intravenous Pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatments, which include targeted therapy. Based on geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. 

The major players in the Germany bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and others. The market players are contributing significantly to the market growth, by the adoption of various business strategies, such as collaborations, mergers and acquisitions, product portfolio diversification, and more.

Recent Developments 

• In August 2024, Janssen-Cilag International NV announced that the European Commission (EC) has approved BALVERSA® (erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic Urothelial Carcinoma (mUC). The medication harbors susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. 

• In June 2024, positive results from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of Event-Free Survival (EFS) and the key secondary endpoint of Overall Survival (OS) versus neoadjuvant chemotherapy for patients with Muscle-Invasive Bladder Cancer (MIBC). During the trial, patients were treated with Imfinzi in combination with neoadjuvant chemotherapy before cystectomy (surgery to remove the bladder) followed by Imfinzi as adjuvant monotherapy.  

• In May 2024, patients with metastatic urothelial cancer and increased expression of the NECTIN4 gene demonstrated better response to antibody treatment than patients with reduced gene expression, according to recent findings published in the Journal of Clinical Oncology. The study identified that tumors with amplification of NECTIN4 had a 96% response to enfortumab vedotin, compared to only 32% in non-amplified.

• In January 2024, Merck KGaA announced new real-world data that reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENCIO® (avelumab) maintenance as a standard of care for eligible patients with locally advanced or metastatic Urothelial Carcinoma (UC) who do not progress on first-line chemotherapy. Real-world studies that confirm median Overall Survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy, in the data. It also offers insights into treatment sequencing outcomes in the real world, with the first analysis of OS by next-line treatment, including in patients who received an Antibody-Drug Conjugate (ADC) such as enfortumab vedotin after the JAVELIN Bladder regimen. 

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-bladder-cancer-market